United Therapeutics Co. (NASDAQ:UTHR) Shares Acquired by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. raised its stake in United Therapeutics Co. (NASDAQ:UTHR) by 20.4% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,584 shares of the biotechnology company’s stock after acquiring an additional 608 shares during the period. Crossmark Global Holdings Inc.’s holdings in United Therapeutics were worth $1,284,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Renaissance Technologies LLC boosted its position in United Therapeutics by 1.1% during the 2nd quarter. Renaissance Technologies LLC now owns 2,174,692 shares of the biotechnology company’s stock worth $692,748,000 after acquiring an additional 22,978 shares during the period. LSV Asset Management increased its stake in shares of United Therapeutics by 82.5% during the 2nd quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock worth $307,837,000 after purchasing an additional 436,851 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of United Therapeutics by 4.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 585,969 shares of the biotechnology company’s stock valued at $186,656,000 after purchasing an additional 22,683 shares in the last quarter. Pacer Advisors Inc. lifted its stake in shares of United Therapeutics by 19.6% in the 2nd quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company’s stock valued at $178,972,000 after purchasing an additional 92,240 shares during the last quarter. Finally, Swedbank AB bought a new stake in United Therapeutics during the first quarter worth approximately $97,316,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Trading Down 0.1 %

Shares of United Therapeutics stock opened at $400.45 on Thursday. The firm has a market capitalization of $17.88 billion, a PE ratio of 17.59, a price-to-earnings-growth ratio of 1.17 and a beta of 0.56. The firm’s 50 day moving average is $361.85 and its 200 day moving average is $326.24. United Therapeutics Co. has a 1 year low of $208.62 and a 1 year high of $417.82.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.16 by $0.23. The firm had revenue of $748.90 million during the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company’s revenue for the quarter was up 22.9% on a year-over-year basis. During the same quarter last year, the firm earned $5.38 earnings per share. As a group, research analysts anticipate that United Therapeutics Co. will post 25.1 earnings per share for the current year.

Wall Street Analyst Weigh In

UTHR has been the topic of a number of recent research reports. Bank of America decreased their target price on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a research report on Thursday, August 1st. LADENBURG THALM/SH SH upped their price target on United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Jefferies Financial Group increased their target price on shares of United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a research report on Monday, September 23rd. The Goldman Sachs Group boosted their price target on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research report on Friday, November 1st. Finally, TD Cowen lifted their target price on shares of United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, October 21st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $370.86.

Insider Activity

In related news, CEO Martine A. Rothblatt sold 269 shares of the stock in a transaction on Monday, August 26th. The shares were sold at an average price of $348.41, for a total transaction of $93,722.29. Following the transaction, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $45,293.30. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Nilda Mesa sold 224 shares of United Therapeutics stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $412.28, for a total transaction of $92,350.72. Following the transaction, the director now owns 5,783 shares of the company’s stock, valued at $2,384,215.24. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Martine A. Rothblatt sold 269 shares of the stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $348.41, for a total transaction of $93,722.29. Following the completion of the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $45,293.30. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 113,396 shares of company stock valued at $42,175,418 in the last ninety days. 11.90% of the stock is owned by company insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.